Protocol Purpose Sample Clauses
The "Protocol Purpose" clause defines the main objective or intended use of a specific protocol within an agreement. It typically outlines the scope of activities, processes, or transactions that the protocol governs, such as data sharing, communication standards, or operational procedures between parties. By clearly stating the protocol's purpose, this clause ensures all parties have a mutual understanding of its application, thereby reducing ambiguity and helping to prevent disputes over the protocol's intended use.
Protocol Purpose. The Commonwealth may only claim FFP for DSRIP expenditures in accordance with the DSRIP Protocol. The DSRIP Protocol: Outlines the context, goals, and outcomes that the Commonwealth seeks to achieve through payment reform; Specifies the allowed uses for DSRIP funding, and the methodologies/process by which the Commonwealth will determine how to distribute DSRIP funding and ensure robust oversight of said funds; Specifies requirements for the DSRIP Participation Plans and Budgets that ACOs and CPs are required to submit and have approved by the Commonwealth; Specifies requirements for how the Commonwealth will procure and oversee any statewide investments in support of the key goals of the demonstration.
Protocol Purpose. The objective of this protocol is to specify a pathway and associated responsibilities for children and families whose needs cross between health service Divisions and the Child and Family Agency. This seeks to ensure that services are: Child and family centred Vulnerable adult centred Not duplicated or fragmented Clear in relation to roles and responsibilities Of high quality with positive outcomes for children and families Transparent Fair and equitable for both service users and providers Based on shared funding across HS E Divisions and across agencies, where necessary Based on flexible allocation and usage of resources commensurate with assessed needs as set out in the care plan Based on best value for money
Protocol Purpose. This Phase 2 pilot study is a randomized, double-blind dose response study in 12 subjects comparing the effects of low and full dose MDMA as an adjunct to manualized psychotherapy. Seven subjects will be randomized to the full dose condition of 125mg of MDMA and five subjects will be randomized to the low dose condition of 40mg of MDMA. Stage 1 of the study will consist of two blinded experimental sessions and one open-label experimental session of manualized MDMA-assisted psychotherapy, each lasting six to eight hours and scheduled three to five weeks apart, within a moderate course of non-drug psychotherapy. The study will be unblinded one month after the second experimental session in Stage 1 after completion of outcome measures, which constitutes the primary endpoint assessment. After unblinding low dose subjects will have the opportunity to cross over to open-label Stage 2 and only full dose subjects will complete the third open-label experimental session. A blinded IR will assess the severity of PTSD symptoms at baseline, at the primary endpoint one month after the second experimental session, two months after the third open-label experimental session and at equivalent points in Stage 2. All subjects will complete a long-term follow-up visit 12 months after their final experimental session in either Stage 1 or Stage 2. This study will provide an estimate of effect size based on dose response of PTSD symptoms to MDMA- assisted psychotherapy. Three therapy teams will conduct psychotherapy visits according the treatment manual provided. Teams will include two main licensed therapists who will work together as co- therapists for the first two subjects. The remaining subjects will be divided between the three teams, with two consisting of a licensed therapist with an intern as a co-therapist, in addition to the experienced team. Information will be collected regarding consistency and response between the teams by reviewing adherence criteria and therapeutic alliance in blinded videos of therapy sessions. This study will also continue the refinement of the treatment manual.